Christoph Wiessner, PhD, is the chief operating officer and founder of Asceneuron S.A. He obtained his PhD in the department of Hartmut Michel at the Max-Planck-Institute for biophysics in Frankfurt, Germany. He then led a laboratory at the Max-Planck-Institute for Neurological Research in Cologne, Germany in the department of Konstantin-Alexander Hossmann and concluded this work with a habilitation in experimental neurology.

Dr. Wiessner has more than 20 years of experience in neuroscience and drug discovery with a focus on neurodegenerative diseases and an established track record of generating clinical candidate molecules. At Novartis in Basel, Switzerland, he headed the CNS Target and Lead Discovery Unit. There, he also led the research team for CAD106, a vaccine for Alzheimer’s disease, currently in Phase II/III testing. At Merck Serono in Geneva, Switzerland, he was director of the neurodegenerative diseases department. Dr. Wiessner has authored more than sixty peer-reviewed publications, reviews and book chapters.